目的 观察阿加曲班注射液对急性脑梗死患者的有效性和安全性。方法 2010年12月—2012年12月在中国人民解放军第254医院住院的急性脑梗死患者60例随机分为治疗组（30例）和对照组（30例），两组患者均给予降脂、调控血压、控制血糖等对症支持治疗，对照组在此基础上口服阿司匹林片，1 片/次，1 次/d；治疗组给予阿加曲班注射液，第1、2天每天用阿加曲班注射液60 mg，以500 mL生理盐水稀释，24 h持续静脉滴注；其后5 d每天用阿加曲班注射液10 mg以250 mL生理盐水稀释，分早晚2次持续静脉滴注，每次3 h，两组均连续治疗7 d。观察、统计两组患者治疗7、14 d的NIHSS评分改善情况和不良反应发生情况。结果 两组治疗后7、14 d与治疗前比较NIHSS评分均明显降低，差异有统计学意义（P＜0.05）；治疗后，治疗组较对照组降低更明显，两组差异有统计学意义（P＜0.05）。治疗组与对照组总有效率分别为93.3%、76.7%，两组比较差异有统计学意义（P＜0.05）。两组患者均无严重不良反应发生。结论 阿加曲班注射液对急性脑梗死有较好的治疗效果，且无不良反应发生。

Objective To evaluate the efficacy and safety of Argatroban Injection in the treatment of the patients with acute cerebral infarction. Methods The patients (60 cases) diagnosed as acutecerebral infarction in Chinese PLA 254 Hospital from December 2010 to December 2012 were randomly divided into treatment (30 cases) and control (30 cases) groups. The two groups were given the treatment to reduce blood fat, and control blood pressure and sugar. In addition, the patients in the control group was po administered with Aspirin, 1 pill/time, once daily. The treatment group was treated with Argatroban Injection (60 mg diluted with 500 mL physiological saline) through 24 h continuous iv pump infusion on the first 2 d. The next 5 d they were treated with Argatroban Injection (10 mg diluted with 250 mL physiological saline), through continuous 3 h iv infusion twice daily in the morning and evening. The patients in the two groups were treated for 7 d. NIHSS scoring and adverse reactions were observed and evaluated after the treatment for 7 d and 14 d, at the same time. Results Within 7 d and 14 d after the treatment, the NIHSS scores of the patient in the two groups were significantly lower than those before the treatment (P < 0.05), and the difference between the two groups was statistically significant (P < 0.05). The efficiency for the patients both in the treatment and control groups were 93.3% and 76.7% with the significant difference (P < 0.05). There was no adverse reaction in the two groups. Conclusion Argatroban Injection has an accurate curative effect on the progressive cerebral infarction, but has no adverse reaction.